RT期刊文章SR电子T1肠内Levetiracetam能提供一个新的治疗选择急性引发癫痫患者在资源有限的环境中?乔(P1.277)摩根富首页林明神经学神经病学FD Lippincott Williams &威尔金斯SP P1.277 VO 86是16补充A1格雷琴Birbeck A1卡尔Seydel A1埃德蒙Capperelli A1分数Dzinjalamala A1苏珊赫尔曼A1 Samah Abdel Baki A1麦克弗森Mallewa A1哈立德易卜拉欣A1弗朗西斯Muwalo A1尼曼Toto A1道格拉斯postel A1约瑟夫·加德纳A1 Terrie泰勒年2016 UL //www.ez-admanager.com/content/86/16_Supplement/P1.277.abstract AB目的:评估肠内levetiracetam (eLVT)对急性发作症状管理在资源有限的环境背景:急性引发癫痫发作和癫痫持续状态是常见的在资源有限的环境中,但发作控制是一个挑战,因为常用药物(巴比妥酸盐)抑制呼吸和通气支持并不普及。Levetiracetam,一种新的抗癫痫剂和一些数据支持其使用在癫痫持续状态,不会引起呼吸抑制。虽然肠外配方对低收入国家来说过于昂贵,肠内公式是负担得起的。方法:增大剂量,药代动力学(Pk) eLVT和开放标签研究的临床试验eLVT与苯巴比妥(PB)控制癫痫脑型疟疾患儿(CM)发作。连续脑电图是用于确定的主要结果;没收自由75年[percnt]的孩子24小时后eLVT负载在PK与癫痫的临床试验研究和分钟。结果:40毫克/公斤负荷然后30毫克/公斤12小时7/7患者是有效的。在4小时内,药物浓度在治疗范围内(20 - 50微克/毫升)。Post-dose等离子LVT水平可预测,从公布的数据没有显著差异。 These findings were replicated within the clinical trial. Forty children were randomized (19 eLVT, 21 PB), 20 males, mean age 41.6 months (range 24-84). The groups did not differ on demographic or clinical characteristics. Breakthrough seizures occurred in 4 children in each group (LVT 165 vs. PB 398 minutes with seizure; p>0.05). Safety failures requiring discontinuation of treatment were higher in the PB group (5/21 PB vs. 0/19 LVT; p=0.018) and 5/6 deaths were in the PB group with death attributed to the underlying CM by the study monitors. Conclusions: Enteral levetiracetam may offer an affordable, feasible and significantly safer option for the management of acute provoked seizures in critically ill children in resource-limited settings where no ventilatory support is available.Disclosure: Dr. Birbeck has received research funding from the US NIH, the Dana Foundation and the AMA Foundation. Dr. Seydel has nothing to disclose. Dr. Capperelli has nothing to disclose. Dr. Dzinjalamala has nothing to disclose. Dr. Herman has received personal compensation for activities with Biotie, Inc. as a consultant, and with UCB Pharma, Sage Pharmaceuticals, Acorda Therapeutics, Inc. as local PI for investigator-initiated clinical trial. Dr. Abdel Baki has received personal compensation for activities with Bio-Signal Company as an employee. Dr. Mallewa has nothing to disclose. Dr. Ibrahim has nothing to disclose. Dr. Muwalo has nothing to disclose. Dr. Toto has nothing to disclose. Dr. Postels has nothing to disclose. Dr. Gardiner has nothing to disclose. Dr. Taylor has nothing to disclose.Saturday, April 16 2016, 8:30 am-7:00 pm